Home › Trials › NCT04333524

Evaluating PET scans for Marginal Zone Lymphoma

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis

Observational International Extranodal Lymphoma Study Group (IELSG) · NCT04333524

This study is testing if PET scans can help doctors better understand and predict outcomes for patients with Marginal Zone Lymphoma.

Quick facts

Study typeObservational
Enrollment350 (estimated)
Ages18 Years and up
SexAll
SponsorInternational Extranodal Lymphoma Study Group (IELSG) Academic / other
Drugs / interventionschemotherapy
Locations25 sites (Dijon and 24 other locations)
Trial IDNCT04333524 on ClinicalTrials.gov

What this trial studies

This study aims to assess the role of PET scans in staging and predicting outcomes for patients with Marginal Zone Lymphoma (MZL). It is a multicenter retrospective analysis utilizing existing PET scan data from patients enrolled in previous clinical studies. The study will analyze PET scans alongside CT scans and other staging procedures to determine their effectiveness. A panel of nuclear medicine physicians will conduct a blinded independent review of the scans to ensure accurate evaluation.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 with histologically confirmed Marginal Zone Lymphoma and available PET and CT scan data.

Not a fit: Patients with Non-Hodgkin Lymphoma types other than Marginal Zone Lymphoma will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the accuracy of staging and treatment response assessment for patients with Marginal Zone Lymphoma.

How similar studies have performed: Other studies have shown promising results in using PET scans for lymphoma assessment, indicating that this approach is supported by prior research.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. One of the following subtypes of Histology confirmed Indolent non-follicular B-cell lymphoma:

   * Splenic MZL (bone marrow histology and/or splenic tissue);
   * Extranodal MZL or MALT (tissue biopsy);
   * Nodal MZL (lymph node biopsy).
2. Age over 18.
3. Availability of details on clinical presentation, treatment details and results, and on follow-up.
4. Execution of PET at diagnosis or/and at end of treatment or/and at relapse.
5. Execution of CT scan with iodine contrast medium at diagnosis and at assessment of response.
6. Patients with histologically confirmed marginal zone lymphomas according to the current WHO classification are registered in the study. Diagnosis based on tru-cut core-needle biopsies are permitted in the study.
7. Written informed consent.

Exclusion Criteria:

1. Patients with a diagnosis of Non Hodgkin Lymphoma other than MZL.
2. Scans images not available for whatever reason.
3. Cases diagnosed on fine needle aspiration cytology only.

Where this trial is running

Dijon and 24 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Marginal Zone Lymphoma
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.